ArticleWorld journal of microbiology & biotechnology2025
Characterization of L. gallinarum Y86: heat-stable antimicrobials and gastrointestinal adaptation.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactobacillus gallinarum Y86, isolated from broiler ileal mucosa under strict anaerobiosis (85% N₂/10% CO₂/5% H₂), demonstrates significant potential as a microbial feed additive for antibiotic-free farming. 16 S rRNA sequencing (99.79% identity to L. gallinarum ATCC 33199; GenBank ON248243) confirmed its taxonomy. Stationary-phase cultures secreted a heat-stable antimicrobial that produced inhibition zones of 21.53 ± 0.34 mm against Salmonella enterica serovar pullorum and 11.90 ± 0.52 mm against Staphylococcus aureus, retaining 87.30% activity after 120 °C for 15 min; sensitivity to trypsin and lipase indicates a proteolipid nature. Y86 endured pH 2.0 for 3 h (63.37% survival) before programmed lysis at 4 h, then recovered to 92.44% viability under intestinal conditions and maintained 45.36% viability in 0.5% bile. High surface hydrophobicity (85.71%) drove auto-aggregation to 97.99% within 24 h, supporting strong epithelial adhesion. The strain was susceptible to β-lactams, macrolides, and vancomycin, intrinsically resistant to tetracyclines and quinolones, and non-haemolytic, meeting EFSA-QPS safety criteria. Collectively, its thermostable antimicrobial production, timed gastric lysis, intestinal resilience, and proven safety identify Y86 as an industrially compatible candidate for antibiotic-free poultry feeds, advancing microbiota-based alternatives to growth-promoting antibiotics.
Indexed as
Identifiers
41474508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.